Alivus Life Sciences Limited
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
What Alivus files
- Investor Meet54
- Others29
- Updates18
- Important9
- Board Meeting8
- PPTs7
Alivus Life Sciences (formerly Glenmark Life Sciences) reported FY26 turnover of ₹2,552 Cr & net worth of ₹3,332 Cr. A flash fire incident resulted in ₹0.29 Cr environmental compensation. Company progresses towards 2027 water neutrality and 2030 carbon neutrality goals. Noted 47 customer complaints and 2 employee/worker fatalities.
Alivus Life Sciences allotted 32,000 equity shares under its Employee Stock Option Scheme, increasing the paid-up share capital to approximately 24.55 Cr. This operational update slightly expands employee ownership.
Alivus Life Sciences experienced a fire at one production block at its Dahej facility, affecting a portion of intermediate manufacturing. API production in that block and six other blocks remain fully operational. The company expects prompt resumption of API and intermediate production, leading to a few delayed shipments.
Alivus Life Sciences (formerly Glenmark Life Sciences) reported FY25 turnover of ₹23,869 Cr and net worth of ₹28,174 Cr, with strong exports comprising 51.7% of sales to over 75 countries. The company is actively pursuing sustainability, significantly reducing its carbon footprint and improving water efficiency. Key operational improvements include adopting...
Alivus Life Sciences has received a favorable update from the USFDA concerning its API manufacturing facility in Dahej, Gujarat. Following a recent inspection, the USFDA has issued an Establishment Inspection Report (EIR) with a "No Action Indicated" (NAI) classification. This positive development confirms the facility's adherence to regulatory standards, ensuring...